ImmuneOnco is a HK-listed (HK.1541), clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer and other diseases. The most advanced program is phase III timdarpacept (IMM01), an SIRPα-IgG1 Fc to treat higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and classic Hodgkin lymphoma. The company recently reached a collaboration with Instil Bio (Nasdaq: TIL) to further develop and commercialize IMM2510, a VEGFxPD-L1 bispecific antibody, and IMM27M, a next-generation anti-CTLA-4 antibody, globally outside of Greater China for a total deal value above USD 2 billion. We are moving fast on the clinical development of the programs. The rest of pipeline focused on bispecific antibodies and fusion proteins targeting cancer, metabolic diseases and autoimmune diseases.